Senti Biosciences Holdings (SNTI) Share-based Compensation (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Share-based Compensation of $1.4 million for Q4 2025, up 135.54% year-over-year from $605000.0 in Q4 2024, and down 8.12% quarter-over-quarter from $1.6 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Share-based Compensation (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Share-based Compensation history runs 5 years deep, the most recent figure standing at $1.4 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 135.54% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $5.7 million (up 225.13% YoY), while the FY2025 annual figure was $5.7 million, up 225.13% from the prior year.
- Share-based Compensation for Q4 2025 stood at $1.4 million, down from $1.6 million in the prior quarter.
- The five-year high for Share-based Compensation was $9.2 million in Q2 2022, with the low at -$2.0 million in Q3 2023.
- The 5-year median for Share-based Compensation is $1.3 million (2024), against an average of $1.8 million.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 473.61% in 2022, then tumbled 187.34% in 2023.
- Senti Biosciences Holdings' Share-based Compensation stood at $735000.0 in 2021, then jumped by 473.61% to $4.2 million in 2022, then slumped by 51.04% to $2.1 million in 2023, then slumped by 70.69% to $605000.0 in 2024, then jumped by 135.54% to $1.4 million in 2025.
- Business Quant data shows SNTI's Share-based Compensation at $1.4 million in Q4 2025, $1.6 million in Q3 2025, and $1.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Senti Biosciences Holdings | 13.66 Mn | 13.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.43 Mn |
| Dec 31, 2025 | 1.43 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.53 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 605,000.00 |
| Dec 31, 2024 | 605,000.00 |
| Sep 30, 2024 | 668,000.00 |
| Sep 30, 2024 | 668,000.00 |
| Jun 30, 2024 | -776,000.00 |
| Jun 30, 2024 | -776,000.00 |
| Mar 31, 2024 | 1.26 Mn |
| Mar 31, 2024 | 1.26 Mn |
| Dec 31, 2023 | 2.06 Mn |
| Dec 31, 2023 | 2.06 Mn |
| Sep 30, 2023 | -2.00 Mn |
| Sep 30, 2023 | -2.00 Mn |